Abstract
There is a well-documented "geographic gap" in vaccine performance, where populations in sub-Saharan Africa often mount lower immune responses compared to those in Europe or North America. One leading hypothesis suggests that chronic exposure to parasitic worms (helminths) modulates the host immune system, potentially dampening vaccine efficacy. This study evaluated the association between helminth exposure and the immune response to the two-dose heterologous Ebola vaccine regimen (Ad26.ZEBOV and MVA-BN-Filo) using samples from three international clinical trials (EBL2001, EBL2002, and EBL3001). While helminth exposure was associated with significant changes in baseline inflammatory and activation markers, it did not significantly impair the concentration of Ebola virus glycoprotein (EBOV GP) binding antibodies post-vaccination. These findings suggest that the Ad26.ZEBOV, MVA-BN-Filo regimen is robust against the immunomodulatory effects of helminth pre-exposure.
Introduction
Vaccine efficacy often varies by geography, with lower immunogenicity frequently observed in tropical, low-income regions. The "helminth hypothesis" posits that endemic parasitic infections reprogram the human immune system toward a Th2-biased and regulatory environment to facilitate parasite survival. This environment may, in turn, suppress the Th1-type responses typically required for effective viral vaccines. This study investigates whether such exposure influences the response to the Janssen Ebola vaccine regimen, which has been critical in managing recent outbreaks.
Methods
The researchers conducted a cross-sectional analysis of serum samples from 367 participants across three major clinical trials:
- EBL2001: Participants in the UK and France.
- EBL2002: Participants in Burkina Faso, Côte d’Ivoire, Kenya, and Uganda.
- EBL3001: Participants in Sierra Leone.
Helminth exposure was assessed via ELISA, detecting IgG antibodies against Schistosoma mansoni, Acanthocheilonema viteae, and Strongyloides ratti. Additionally, Luminex technology was employed to measure 41 baseline immunological analytes (cytokines and chemokines). The primary outcome was the concentration of IgG antibodies specific to the Ebola virus glycoprotein (EBOV GP), measured 21 days after the second dose and one year after the first dose.
Key Results
Prevalence and Baseline Immune Profiles
Of the 367 participants, 21.3% (n=78) tested positive for at least one helminth marker at baseline. Prevalence varied significantly by geography, peaking at 34% in Uganda compared to 9.4% in the UK.
Helminth-positive individuals exhibited a distinct baseline immune profile. Five markers were significantly lower (p < .003) in these participants: CCL2/MCP1, FGFbasic, IL-7, IL-13, and CCL11/Eotaxin. The reduction in IL-7 (a T-cell growth factor) and IL-13 (a Th2 cytokine) confirms that parasitic exposure actively modulates the host's systemic immune environment prior to vaccination.
Vaccine Immunogenicity
Despite the altered baseline immune states, the vaccine regimen remained highly effective. Multivariable linear regression models, adjusted for age and study group, found no significant association between helminth exposure and EBOV GP antibody concentrations at either 21 days post-dose 2 (p = 0.19) or one year post-dose 1 (p = 0.85).
Geographic and Demographic Factors
While helminths did not explain the variance, geography remained a significant factor; European participants generally mounted higher antibody responses than African participants even after adjusting for helminth status. Additionally, age was a strong predictor of response, with children mounting higher antibody concentrations than adults.
Discussion and Conclusion
This study demonstrates that while helminth exposure significantly alters the baseline inflammatory landscape, it does not appear to be the primary driver of the geographic gap in Ebola vaccine response. The Ad26.ZEBOV, MVA-BN-Filo regimen appears robust enough to overcome the immunomodulatory environment associated with helminth pre-exposure.
Limitations of the study include the use of antibody-based ELISA tests, which may indicate past exposure rather than active, current infection. Future research into the geographic variability of vaccine responses should shift focus toward other environmental factors, such as the gut microbiota, nutrition, or other co-infections like malaria, which may play a more decisive role in shaping vaccine-induced immunity.
Summary updated